Hutchinson-Gilford Progeria Syndrome (HGPS)

Recently, U.S.-based Sentynl Therapeutics, a part of Zydus Lifesciences, signed an agreement with South Korea’s PRG S&T to develop a drug called Progerinin. This medicine is being developed as an oral pill to treat Hutchinson-Gilford Progeria Syndrome, a rare genetic condition that causes rapid aging in children.
This development is significant because Progerinin represents a potential targeted treatment for a disease that currently has very limited therapeutic options.

What is Hutchinson-Gilford Progeria Syndrome (HGPS)?

Hutchinson-Gilford Progeria Syndrome, commonly known as progeria, is an extremely rare genetic disorder that causes children to age rapidly, beginning in early childhood. The condition is very uncommon and occurs in about 1 in 4 million live births worldwide. Children with this disorder usually appear healthy at birth but start showing signs of premature aging within the first one to two years of life.
HGPS is one of the rarest genetic disorders, yet it has severe and life-limiting effects.

Causes of Progeria

Progeria is caused by a mutation in the LMNA gene, which is responsible for producing a protein called lamin A. Lamin A plays a crucial role in maintaining the structural stability of the nucleus in cells. Due to this mutation, an abnormal protein called progerin is produced instead of normal lamin A. Progerin weakens the cell nucleus and gradually damages cells, leading to premature aging. Most cases occur due to a new spontaneous mutation, meaning there is usually no family history of the disease.
The disease is driven by the buildup of progerin, an abnormal protein that damages cells and accelerates aging.

Symptoms and Characteristics

Children with progeria experience slow growth and do not gain weight as expected. Despite this, their intellectual abilities and motor skills develop normally. Over time, they develop distinct physical features such as hair loss, prominent eyes, wrinkled skin, a thin beaked nose, a small face relative to head size, and loss of fat under the skin.
The condition affects physical appearance and growth but not intelligence or motor development.

Complications and Life Expectancy

Progeria is a fatal condition, with an average life expectancy of around 14.5 years, although some individuals may live into their early twenties. The primary cause of death is complications related to atherosclerosis, a condition in which plaque builds up in the arteries, making them stiff and increasing the risk of heart attack and stroke at a very young age.
Cardiovascular complications are the leading cause of death in children with progeria.

Conclusion

Hutchinson-Gilford Progeria Syndrome is a rare but devastating genetic disorder caused by a mutation in the LMNA gene that leads to rapid aging. The recent development of Progerinin offers new hope for treatment.